{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:15:15Z","timestamp":1787620515243,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013917","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000}}],"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203134\/Z\/16\/Z"],"award-info":[{"award-number":["203134\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["203134\/Z\/16\/Z"],"award-info":[{"award-number":["203134\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["224024\/Z\/21\/Z"],"award-info":[{"award-number":["224024\/Z\/21\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    Chagas\u2019 disease, caused by infection with the protozoan parasite\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    , is a potentially fatal condition for which new treatments are urgently needed. Due to the lack of validated drug targets, phenotypic screening followed by target deconvolution is the dominant approach in Chagas\u2019 disease drug discovery. However, as most phenotypic screening hits act through a small number of promiscuous targets, implementation of counter-screening methodology for these targets as early as possible in the workflow is essential to enable prioritisation of compounds with novel Modes of Action (MoA). Here, we demonstrate that untargeted metabolomic profiling using liquid chromatography mass spectrometry (LC-MS) can reliably identify compounds that act through one of the most common targets, cytochrome\n                    <jats:italic>b<\/jats:italic>\n                    . Treatment of epimastigote form\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    in culture with cytochrome\n                    <jats:italic>b<\/jats:italic>\n                    inhibitors resulted in rapid and pronounced perturbation of the metabolome. We identified a signature of 79 metabolites that were differentially expressed by at least 2-fold (p\u2009&lt;\u20090.05). Unsupervised multivariate analysis using these features allowed clear separation of cytochrome\n                    <jats:italic>b<\/jats:italic>\n                    inhibitors from compounds acting through other MoA, and through disruption of oxidative phosphorylation by other mechanisms. Flexibility was observed in this cytochrome\n                    <jats:italic>b<\/jats:italic>\n                    signature between experiments, and depending on the compounds used, suggesting that this approach could be readily implemented in other laboratories. Triage of cytochrome\n                    <jats:italic>b<\/jats:italic>\n                    inhibitors early in the Chagas\u2019 disease drug discovery workflow using untargeted metabolomics will aid in prioritisation of medicinal chemistry resources towards compounds acting through novel mechanisms.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0013917","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:45:31Z","timestamp":1768934731000},"page":"e0013917","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Untargeted metabolomics for triaging of cytochrome b inhibitors during Chagas\u2019 disease drug discovery"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6328-1178","authenticated-orcid":true,"given":"A. Kenneth","family":"MacLeod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay B.","family":"Tulloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wyllie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"pntd.0013917.ref001","unstructured":"World Health Organisation. Chagas disease (American trypanosomiasis) [Internet]. Available from: https:\/\/www.who.int\/health-topics\/chagas-disease"},{"issue":"2","key":"pntd.0013917.ref002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1128\/jcm.18.2.327-330.1983","article-title":"Direct micromethod for diagnosis of acute and congenital Chagas\u2019 disease","volume":"18","author":"H Feilij","year":"1983","journal-title":"J Clin Microbiol"},{"issue":"30","key":"pntd.0013917.ref003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMra1410150","article-title":"Chagas\u2019 disease","volume":"373","author":"C Bern","year":"2015","journal-title":"N Engl J Med"},{"key":"pntd.0013917.ref004","article-title":"Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure","volume":"7","author":"FJ S\u00e1nchez-Vald\u00e9z","year":"2018","journal-title":"Elife"},{"issue":"10","key":"pntd.0013917.ref005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/s41579-019-0238-x","article-title":"Protozoan persister-like cells and drug treatment failure","volume":"17","author":"MP Barrett","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"pntd.0013917.ref006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrmicro.2016.193","article-title":"Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need","volume":"15","author":"MC Field","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"pntd.0013917.ref007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","volume":"21","author":"M De Rycker","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"pntd.0013917.ref008","article-title":"The critical role of mode of action studies in kinetoplastid drug discovery","volume":"3","author":"AH Fairlamb","year":"2023","journal-title":"Front Drug Discov (Lausanne)"},{"issue":"9","key":"pntd.0013917.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004014","article-title":"Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease","volume":"9","author":"J Riley","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0013917.ref010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/acsinfecdis.9b00426","article-title":"The Qi Site of Cytochrome b is a promiscuous drug target in Trypanosoma cruzi and Leishmania donovani","volume":"6","author":"RJ Wall","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"1","key":"pntd.0013917.ref011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/iub.1697","article-title":"Direct and indirect approaches to identify drug modes of action","volume":"70","author":"LB Tulloch","year":"2018","journal-title":"IUBMB Life"},{"issue":"3","key":"pntd.0013917.ref012","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1039\/D1MO00017A","article-title":"Metabolomics in infectious diseases and drug discovery","volume":"17","author":"V Tounta","year":"2021","journal-title":"Mol Omics"},{"issue":"1","key":"pntd.0013917.ref013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/S0031182013000814","article-title":"Determination of antiprotozoal drug mechanisms by metabolomics approaches","volume":"141","author":"DJ Creek","year":"2014","journal-title":"Parasitology"},{"issue":"1","key":"pntd.0013917.ref014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1087057114551519","article-title":"Metabolomic-based strategies for anti-parasite drug discovery","volume":"20","author":"IM Vincent","year":"2015","journal-title":"J Biomol Screen"},{"key":"pntd.0013917.ref015","doi-asserted-by":"crossref","unstructured":"Edgar RCS, Malcolm TR, Siddiqui G, Giannangelo C, Counihan NA, Challis M. Species antimalarial activity. 2024;15(6).","DOI":"10.1128\/mbio.00966-24"},{"key":"pntd.0013917.ref016","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.92990.3","article-title":"Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as an antimalarial strategy","volume":"13","author":"C Giannangelo","year":"2024","journal-title":"Elife"},{"issue":"4","key":"pntd.0013917.ref017","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11306-022-01880-0","article-title":"Trypanosoma brucei: Metabolomics for analysis of cellular metabolism and drug discovery","volume":"18","author":"F Fall","year":"2022","journal-title":"Metabolomics"},{"issue":"5","key":"pntd.0013917.ref018","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acschembio.8b00204","article-title":"Metabolic Clustering Analysis as a Strategy for Compound Selection in the Drug Discovery Pipeline for Leishmaniasis","volume":"13","author":"EG Armitage","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"11","key":"pntd.0013917.ref019","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1128\/AAC.01224-16","article-title":"Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways","volume":"60","author":"EL Allman","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"pntd.0013917.ref020","doi-asserted-by":"crossref","first-page":"6650","DOI":"10.1128\/AAC.01226-16","article-title":"Metabolomics-Based Screening of the Malaria Box Reveals both Novel and Established Mechanisms of Action","volume":"60","author":"DJ Creek","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pntd.0013917.ref021","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2019.11.009","article-title":"Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery","volume":"27","author":"JM Murithi","year":"2020","journal-title":"Cell Chem Biol"},{"key":"pntd.0013917.ref022","doi-asserted-by":"crossref","unstructured":"Simwela NV, Guiguemde WA, Straimer J, Regnault C, Stokes BH, Tavernelli LE, et al. A conserved metabolic signature associated with response to fast-acting anti-malarial agents. 2023;11(6).","DOI":"10.1128\/spectrum.03976-22"},{"issue":"1","key":"pntd.0013917.ref023","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1021\/cb200348m","article-title":"Predicting the in vivo mechanism of action for drug leads using NMR metabolomics","volume":"7","author":"S Halouska","year":"2012","journal-title":"ACS Chem Biol"},{"issue":"429","key":"pntd.0013917.ref024","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3973","article-title":"High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds","volume":"10","author":"M Zampieri","year":"2018","journal-title":"Sci Transl Med"},{"key":"pntd.0013917.ref025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12866-016-0696-5","article-title":"Characterization and prediction of the mechanism of action of antibiotics through NMR metabolomics","volume":"16","author":"V Hoerr","year":"2016","journal-title":"BMC Microbiol"},{"issue":"21","key":"pntd.0013917.ref026","doi-asserted-by":"crossref","first-page":"19199","DOI":"10.1021\/acsomega.9b02507","article-title":"Small Polar Hits against S. aureus: Screening, Initial Hit Optimization, and Metabolomic Studies","volume":"4","author":"AST Lim","year":"2019","journal-title":"ACS Omega"},{"key":"pntd.0013917.ref027","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/191144a0","article-title":"Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism","volume":"191","author":"P MITCHELL","year":"1961","journal-title":"Nature"},{"key":"pntd.0013917.ref028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpddr.2022.07.003","article-title":"Sterol profiling of Leishmania parasites using a new HPLC-tandem mass spectrometry-based method and antifungal azoles as chemical probes reveals a key intermediate sterol that supports a branched ergosterol biosynthetic pathway","volume":"20","author":"M Feng","year":"2022","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"726","key":"pntd.0013917.ref029","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg8105","article-title":"Short-course combination treatment for experimental chronic Chagas disease","volume":"15","author":"S Gonz\u00e1lez","year":"2024","journal-title":"Sci Transl Med"},{"key":"pntd.0013917.ref030","article-title":"Anti-trypanosomal quinazolines targeting lysyl-tRNA-synthetase show partial efficacy in a mouse model of acute Chagas disease","author":"LB Tulloch","year":"2025","journal-title":"Sci Transl Med"},{"issue":"2","key":"pntd.0013917.ref031","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1042\/BJ20131033","article-title":"Biochemical and genetic characterization of Trypanosoma cruzi N-myristoyltransferase","volume":"459","author":"AJ Roberts","year":"2014","journal-title":"Biochem J"},{"issue":"1","key":"pntd.0013917.ref032","article-title":"Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas\u2019 Disease","volume":"66","author":"ML Lima","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pntd.0013917.ref033","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11306-007-0082-2","article-title":"Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI)","volume":"3","author":"LW Sumner","year":"2007","journal-title":"Metabolomics"},{"issue":"2","key":"pntd.0013917.ref034","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/0003-9861(58)90383-7","article-title":"Antibiotics as tools for metabolic studies. I. A survey of toxic antibiotics in respiratory, phosphorylative and glycolytic systems","volume":"78","author":"HA Lardy","year":"1958","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"pntd.0013917.ref035","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-5793(68)80008-0","article-title":"Dinitrophenol and valinomycin as uncouplers in isolated chloroplasts","volume":"1","author":"SJD Karlish","year":"1968","journal-title":"FEBS Lett"},{"issue":"3","key":"pntd.0013917.ref036","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells","volume":"162","author":"LB Sullivan","year":"2015","journal-title":"Cell"},{"key":"pntd.0013917.ref037","doi-asserted-by":"crossref","unstructured":"Pereira CA, Bouvier A, de los Milagros Camara M, Miranda MR. Singular features of trypanosomatids\u2019 phosphotransferases involved in cell energy management. 2011;2011.","DOI":"10.4061\/2011\/576483"},{"issue":"7","key":"pntd.0013917.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005058","article-title":"Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease","volume":"11","author":"S Khare","year":"2015","journal-title":"PLoS Pathog"},{"issue":"8","key":"pntd.0013917.ref039","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1128\/AAC.00850-16","article-title":"Targeting the Cytochrome bc1 Complex of Leishmania Parasites for Discovery of Novel Drugs","volume":"60","author":"D Ortiz","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pntd.0013917.ref040","first-page":"1","article-title":"RES-Seq\u2014a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitness","volume":"14","author":"LB Tulloch","year":"2023","journal-title":"Antimicrob Chemother"},{"issue":"1","key":"pntd.0013917.ref041","doi-asserted-by":"crossref","first-page":"10488","DOI":"10.1038\/s41598-017-10041-6","article-title":"Zinc depletion promotes apoptosis-like death in drug-sensitive and antimony-resistance Leishmania donovani","volume":"7","author":"S Saini","year":"2017","journal-title":"Sci Rep"},{"key":"pntd.0013917.ref042","doi-asserted-by":"crossref","first-page":"31078","DOI":"10.1038\/srep31078","article-title":"The N-myristoylome of Trypanosoma cruzi","volume":"6","author":"AJ Roberts","year":"2016","journal-title":"Sci Rep"},{"issue":"7","key":"pntd.0013917.ref043","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/ph14070636","article-title":"Evidence of pyrimethamine and cycloguanil analogues as dual inhibitors of trypanosoma brucei pteridine reductase and dihydrofolate reductase","volume":"14","author":"G Tassone","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"pntd.0013917.ref044","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkv376","article-title":"Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei","volume":"71","author":"S Wyllie","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"pntd.0013917.ref045","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2021.02.008","article-title":"Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial","volume":"28","author":"LS Paradela","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"10","key":"pntd.0013917.ref046","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1021\/acsinfecdis.7b00047","article-title":"Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani","volume":"3","author":"LS Torrie","year":"2017","journal-title":"ACS Infect Dis"},{"issue":"38","key":"pntd.0013917.ref047","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1073\/pnas.1807915115","article-title":"Clinical and veterinary trypanocidal benzoxaboroles target CPSF3","volume":"115","author":"RJ Wall","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pntd.0013917.ref048","first-page":"8","article-title":"Purification of extracellular and intracellular amastigotes of Trypanosoma cruzi from mammalian host-infected cells","author":"A Marques","year":"2011","journal-title":"Protoc Exch"},{"key":"pntd.0013917.ref049","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/978-1-0716-4848-3_26","article-title":"A rapid method for purifying intact Trypanosoma cruzi Amastigotes from host cells, in vitro and in vivo, for downstream \u2019omic analysis","volume":"2982","author":"F Olmo","year":"2026","journal-title":"Methods Mol Biol"},{"issue":"5","key":"pntd.0013917.ref050","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00216-010-4139-0","article-title":"Towards an unbiased metabolic profiling of protozoan parasites: optimisation of a Leishmania sampling protocol for HILIC-orbitrap analysis","volume":"398","author":"R t\u2019Kindt","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"pntd.0013917.ref051","doi-asserted-by":"crossref","unstructured":"Yurekten O, Payne T, Tejera N, Amaladoss FX, Martin C, Williams M. MetaboLights: open data repository for metabolomics. 2024;2024(November 2023):640\u20136.","DOI":"10.1093\/nar\/gkad1045"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013917","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:53:50Z","timestamp":1769540030000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013917"}},"subtitle":[],"editor":[{"given":"Erica","family":"Silberstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013917","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]}}}